Sanofi to Buy Principia Biopharma in $3.4 Billion Deal

The video discusses Santa Fe's acquisition of the U.S. company Principia, focusing on treatments for multiple sclerosis and autoimmune disorders. The acquisition provides Santa Fe access to a promising pipeline of BTK inhibitors. The video also highlights the market impact of a German company's strong rally and the ongoing race for COVID vaccines, with companies like Moderna making significant progress. The coming months are crucial for vaccine developers as they move swiftly through clinical trials, with significant data expected soon.

What are BTK inhibitors and what disorders are they being developed to treat?

What challenges do investors face regarding the expectations of vaccine developers?